Physician profile
Brian A Los
NPI 1497747588
$14,267.25
in general payments reported to CMS, 2019-2025
49 companies · $1,896 in 2025
The $1,896 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,309 · 2020: $1,508 · 2021: $1,787 · 2022: $1,910 · 2023: $2,630 · 2024: $2,226 · 2025: $1,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,727 · Education: $25.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,726.68 |
| Education | $25.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,521.21 | 2019-2025 | |
| Novo Nordisk INC | $1,501.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,380.70 | 2019-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,259.94 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $917.29 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Glaxosmithkline, LLC. | $889.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $888.67 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $871.36 | 2020-2025 | |
| Lilly USA, LLC | $835.00 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $462.51 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $438.28 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $407.81 | 2019-2023 | |
| Exact Sciences Corporation | $298.54 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $265.85 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $227.56 | 2021-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Los listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.